Visual performance of a new multifocal diffractive IOL

Article

Comparative study shows excellent intermediate vision results, high levels of spectacle independence and minimal photic phenoma at night.

Study details

The Diffractiva Diff-aA MIOL is currently under clinical evaluation in a multicentre study in which seven participating University or Private Clinics in France, Austria, UK and Libanon are taking part. A total enrollment of 45 patients (90 eyes) with bilateral cataract and eligible for MIOL implantation has been targeted. Ophthalmic examinations including refraction, monocular and binocular visual acuity for far, intermediate (1 m) and near (40 cm) distances have been scheduled at 1-month, 3-months and 6-months postoperatively. Evaluation of contrast sensitivity and defocus curve has been scheduled at 6 months postoperatively, patient satisfaction (quality-of-life questionnaire) at 3 and 6-months postoperatively.

Recent Videos
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
Marjorie Rah, OD, PhD, FAAO
Josefina Botta, MD, MSc, at ASCRS 2024
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
© 2024 MJH Life Sciences

All rights reserved.